Stocks and Investing Stocks and Investing
Fri, May 13, 2022

Matthew Barcus Maintained (VINC) at Strong Buy with Decreased Target to $11 on, May 13th, 2022


Published on 2024-10-27 21:04:30 - WOPRAI, Matthew Barcus
  Print publication without navigation


Matthew Barcus of Chardan Capital, Maintained "Vincerx Pharma, Inc." (VINC) at Strong Buy with Decreased Target from $14 to $11 on, May 13th, 2022.

Matthew has made no other calls on VINC in the last 4 months.



There is 1 other peer that has a rating on VINC. Out of the 1 peers that are also analyzing VINC, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $28 on, Wednesday, March 30th, 2022
Contributing Sources